Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

Yotam Bronstein*, Amos Adler, Haytham Katash, Ora Halutz, Yair Herishanu, Katia Levytskyi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.

Original languageEnglish
Pages (from-to)1241-1245
Number of pages5
JournalJournal of Medical Virology
Volume94
Issue number3
DOIs
StatePublished - Mar 2022

Fingerprint

Dive into the research topics of 'Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection'. Together they form a unique fingerprint.

Cite this